Opposing effects of membrane-anchored CX3CL1 on amyloid and tau pathologies via the p38 MAPK pathway
about
CX3CL1/CX3CR1 in Alzheimer's Disease: A Target for NeuroprotectionSystematic Review of the Neurobiological Relevance of Chemokines to Psychiatric DisordersFractalkine Signaling and Microglia Functions in the Developing BrainImmunomodulators as Therapeutic Agents in Mitigating the Progression of Parkinson's DiseaseInnate Immunity Fights Alzheimer's DiseaseInflammatory reaction after traumatic brain injury: therapeutic potential of targeting cell-cell communication by chemokinesSelective Brain-Targeted Antagonism of p38 MAPKα Reduces Hippocampal IL-1β Levels and Improves Morris Water Maze Performance in Aged RatsAnalysis of the Role of CX3CL1 (Fractalkine) and Its Receptor CX3CR1 in Traumatic Brain and Spinal Cord Injury: Insight into Recent Advances in Actions of Neurochemokine Agents.Old Maids: Aging and Its Impact on Microglia Function.TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer's disease mouse models.Ccr2 deletion dissociates cavity size and tau pathology after mild traumatic brain injurySuppression of LPS-induced tau hyperphosphorylation by serum amyloid A.Loss of Fractalkine Signaling Exacerbates Axon Transport Dysfunction in a Chronic Model of Glaucoma.Fractalkine in the nervous system: neuroprotective or neurotoxic molecule?The complex contribution of chemokines to neuroinflammation: switching from beneficial to detrimental effects.Central nervous system myeloid cells as drug targets: current status and translational challenges.Modulation of Neuroinflammation in the Central Nervous System: Role of Chemokines and Sphingolipids.Opposing effects of progranulin deficiency on amyloid and tau pathologies via microglial TYROBP network.Impact of Cytokines and Chemokines on Alzheimer's Disease Neuropathological Hallmarks.Role of Atypical Chemokine Receptors in Microglial Activation and Polarization.Targeting neuronal MAPK14/p38α activity to modulate autophagy in the Alzheimer disease brain.The roles of inflammation and immune mechanisms in Alzheimer's disease.TREM2 deficiency exacerbates tau pathology through dysregulated kinase signaling in a mouse model of tauopathy.A microglia-cytokine axis to modulate synaptic connectivity and function.Stimulation of TLR4 Attenuates Alzheimer's Disease-Related Symptoms and Pathology in Tau-Transgenic Mice.Complex role of chemokine mediators in animal models of Alzheimer's Disease.The Inflammatory Continuum of Traumatic Brain Injury and Alzheimer's Disease.Genetically enhancing the expression of chemokine domain of CXCL1 fails to prevent tau pathology in mouse models of tauopathyInflammation: the link between comorbidities, genetics, and Alzheimer's diseaseRoles of Microglial and Monocyte Chemokines and Their Receptors in Regulating Alzheimer's Disease-Associated Amyloid-β and Tau Pathologies
P2860
Q26739374-FE3F46A0-F5A8-43BF-BAA7-E489DC0C1334Q26781639-F234365C-F5F6-4E99-8DC1-AF1DBF21F3F5Q26782935-11B972A5-8C23-4B04-B84B-9A5DE2242C72Q28079187-59E51576-D751-4221-8D39-11E2069FE625Q28081826-E23065A0-5CDD-43B7-AF4B-11E72544D8C6Q28088301-B0B85953-DE19-47C3-8139-F2DDD59AD73DQ28828716-09CBE804-D583-4DE2-BDA9-B96E6EC14515Q30360306-FF7A7244-53BD-41D8-B44E-169B7104D460Q33624540-AF52885B-8445-48AE-9D6B-CDD0B6DC0827Q35161472-5861E2AB-423B-4400-BE20-1065C5307B92Q36346809-C8AB7C80-EACA-45E2-A8BB-3ED789BC63EAQ36529499-E294B324-D10E-46A8-B549-7C618BDD5773Q37440705-E87EE101-E34D-4F23-8DF0-6FDE8E8BE374Q38530348-C6998BBA-4577-45F1-AB56-EA4490688785Q38562255-08A0A95C-C5A9-4294-9F11-9FEDA9B02336Q38658658-85D5D40E-F0D0-4CA7-9EFC-928C6ACDCA1BQ38774697-E2DD6AF9-B776-4274-B698-F2FE536981E6Q39030129-43C391E8-5FFE-4E20-8C2E-ED637D8D17A0Q39186980-415E218F-3368-42A2-A7EF-A5108C19D1CDQ39365708-F47936EA-6C46-48BB-8CFF-23110F355C42Q39547451-29FA502D-4B92-4647-8FD1-86EE4DB8B40EQ42656274-EC21696C-06A6-4513-B0D0-743E7FF3C4BDQ42690758-5A3C7031-7E62-4D44-BC44-ADBAC780CD81Q47990177-7D349780-8417-43B7-9C6C-9CA2FFCFDB3EQ48524916-A47CC54B-290C-406A-B12F-960B9BCA4CF5Q52315330-B12EE12B-8E41-437E-BD16-C296CF944841Q53403638-653422DA-7107-4769-8BDB-086496ECF127Q58699436-76F00061-5684-4B40-A081-0CA3732EA42BQ58700943-1EAB880A-49F9-419A-A705-C2633AEF34BCQ58780923-2545BE55-C8BD-4C91-8C96-73229F67F18D
P2860
Opposing effects of membrane-anchored CX3CL1 on amyloid and tau pathologies via the p38 MAPK pathway
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Opposing effects of membrane-a ...... ogies via the p38 MAPK pathway
@ast
Opposing effects of membrane-a ...... ogies via the p38 MAPK pathway
@en
Opposing effects of membrane-a ...... ogies via the p38 MAPK pathway
@nl
type
label
Opposing effects of membrane-a ...... ogies via the p38 MAPK pathway
@ast
Opposing effects of membrane-a ...... ogies via the p38 MAPK pathway
@en
Opposing effects of membrane-a ...... ogies via the p38 MAPK pathway
@nl
prefLabel
Opposing effects of membrane-a ...... ogies via the p38 MAPK pathway
@ast
Opposing effects of membrane-a ...... ogies via the p38 MAPK pathway
@en
Opposing effects of membrane-a ...... ogies via the p38 MAPK pathway
@nl
P2093
P2860
P50
P1476
Opposing effects of membrane-a ...... ogies via the p38 MAPK pathway
@en
P2093
Bruce T Lamb
Gary E Landreth
Guixiang Xu
Richard M Ransohoff
Sabina Bhatta
Taylor R Jay
P2860
P304
12538-12546
P356
10.1523/JNEUROSCI.0853-14.2014
P407
P577
2014-09-01T00:00:00Z